Patents Assigned to American Gene Technologies International, Inc.
-
Patent number: 11976292Abstract: A non-integrating viral delivery system is disclosed. The system includes a viral carrier, wherein the viral carrier contains a defective integrase gene; a heterologous viral episomal origin of replication; a sequence encoding at least one initiator protein specific for the heterologous viral episomal origin of replication, wherein expression of the sequence encoding the at least one initiator protein specific for the heterologous viral episomal origin of DNA replication is inducible; and at least one gene, gene product, shRNA, siRNA, miRNA, or other RNA of interest.Type: GrantFiled: December 12, 2016Date of Patent: May 7, 2024Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Tyler Lahusen
-
Patent number: 11911458Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: GrantFiled: July 7, 2017Date of Patent: February 27, 2024Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Gary Mansfield
-
Patent number: 11820999Abstract: A lentiviral vector system for expressing a lentiviral particle is disclosed. The lentiviral vector system includes a therapeutic vector. The therapeutic vector comprises a phenylalanine hydroxylase (PAH) sequence for expressing at least one of PAH or a variant thereof, wherein the PAH sequence is truncated.Type: GrantFiled: April 2, 2018Date of Patent: November 21, 2023Assignee: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Charles David Pauza
-
Patent number: 11617760Abstract: The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5? LTR, wherein the 5? LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.Type: GrantFiled: April 12, 2021Date of Patent: April 4, 2023Assignee: American Gene Technologies International Inc.Inventors: Zhennan Lai, Jeffrey A. Galvin
-
Patent number: 11612649Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: GrantFiled: February 12, 2021Date of Patent: March 28, 2023Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeff Galvin
-
Patent number: 11583562Abstract: A lentiviral vector system for expressing a lentiviral particle is disclosed. The lentiviral vector system includes a therapeutic vector, an envelope plasmid, and at least one helper plasmid. The lentiviral vector system can produce a lentiviral particle for inhibiting PARP expression in neuron cells of a subject afflicted with Parkinson's disease.Type: GrantFiled: July 20, 2017Date of Patent: February 21, 2023Assignee: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Charles David Pauza
-
Patent number: 11534450Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.Type: GrantFiled: August 7, 2020Date of Patent: December 27, 2022Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
-
Patent number: 11519006Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.Type: GrantFiled: September 6, 2019Date of Patent: December 6, 2022Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
-
Patent number: 11352646Abstract: Viral vectors, lentiviral particles, and modified cells are disclosed. They encode or express a small RNA capable of targeting the KIF11 gene. In embodiments, the viral vectors and lenti viral particles further comprise and a KIF11 gene whose non-coding region has been modified such that it is resistant to activity by the small RNA.Type: GrantFiled: November 5, 2019Date of Patent: June 7, 2022Assignee: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
-
Publication number: 20220162643Abstract: A lentiviral vector system for expressing a lentiviral particle is disclosed. The lentiviral vector system includes a therapeutic vector. The lentiviral vector system produces a lentiviral particle that encodes a codon-optimized PAH for upregulating PAH expression in the cells of a subject afflicted with phenylketonuria (PKU).Type: ApplicationFiled: June 1, 2020Publication date: May 26, 2022Applicant: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
-
Patent number: 11242527Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.Type: GrantFiled: March 10, 2021Date of Patent: February 8, 2022Assignee: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
-
Publication number: 20210403949Abstract: Viral vectors, lentiviral particles, and modified cells are disclosed. They encode or express a small RNA capable of targeting the KIF11 gene. In embodiments, the viral vectors and lenti viral particles further comprise and a KIF11 gene whose non-coding region has been modified such that it is resistant to activity by the small RNA.Type: ApplicationFiled: November 5, 2019Publication date: December 30, 2021Applicant: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Lingzhi Xiao, Charles David Pauza
-
Patent number: 11090379Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: GrantFiled: October 4, 2019Date of Patent: August 17, 2021Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeff Galvin
-
Patent number: 11007209Abstract: The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5? LTR, wherein the 5? LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.Type: GrantFiled: November 18, 2019Date of Patent: May 18, 2021Assignee: American Gene Technologies International Inc.Inventors: Zhennan Lai, Jeffrey A. Galvin
-
Patent number: 10975374Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.Type: GrantFiled: July 30, 2020Date of Patent: April 13, 2021Assignee: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
-
Patent number: 10888613Abstract: The present invention relates generally to immunotherapy for preventing HIV infection in HIV-negative individuals. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: GrantFiled: January 11, 2017Date of Patent: January 12, 2021Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen
-
Patent number: 10772905Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.Type: GrantFiled: August 2, 2019Date of Patent: September 15, 2020Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Mei-Ling Liou
-
Patent number: 10767183Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.Type: GrantFiled: March 9, 2017Date of Patent: September 8, 2020Assignee: American Gene Technologies International Inc.Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
-
Patent number: 10548914Abstract: The present application discloses a lentiviral transfer system which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5? LTR, wherein the 5? LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional.Type: GrantFiled: December 21, 2011Date of Patent: February 4, 2020Assignee: American Gene Technologies International Inc.Inventors: Zhennan Lai, Jeffrey Galvin
-
Patent number: 10494647Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.Type: GrantFiled: December 12, 2018Date of Patent: December 3, 2019Assignee: American Gene Technologies International Inc.Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen, Jeff Galvin